文献速递鼻科

鼻用莫米松大容量高剂量冲洗对术后慢性鼻窦炎患者HPA轴抑制的可能性

The possibility of short-term hypothalamic-pituitary-adrenal axis suppression with high-volume, high-dose nasal mometasone irrigation in postsurgical patients with chronic rhinosinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2021-09-26

这项前瞻性队列研究纳入14例FESS术后难治性CRS成人患者,接受每日两次大容量鼻窦莫米松冲洗(总剂量4 mg)12周。除1例因关节腔激素注射出现一过性皮质醇降低外,治疗前后晨皮质醇无显著差异(P=0.915),未发现HPA轴抑制证据。

要点

  • 2 mg每日两次大容量鼻窦莫米松冲洗12周未导致HPA轴抑制。
  • 治疗前后晨皮质醇无显著差异(P=0.915),均在正常范围。
  • 1例治疗后皮质醇降低与近期关节腔激素注射有关,复查恢复正常。

核心结论

  • 大容量2 mg每日两次鼻窦莫米松冲洗未在基线皮质醇正常的FESS术后难治性CRS患者中引起HPA轴抑制。

研究设计与样本

  • 前瞻性队列研究,2018年6月至2019年12月从三级诊所招募14例成人患者。

主要发现

  • 完成12周不间断治疗后未发现HPA轴抑制证据(P = 0.915)。
  • 1例治疗后晨血清皮质醇低至1.3 μg/dL,但采血前数日曾接受关节腔激素注射,无症状且复查为12.3 μg/dL。

关键数值与推荐

  • 纳入标准包括年龄>18岁、CRS诊断、既往FESS、治疗前晨皮质醇正常、至少每日两次大容量鼻窦莫米松冲洗(总剂量4 mg)持续12周、治疗后2周内测量晨皮质醇。
  • 排除标准包括可能存在内源性或外源性HPA轴干扰的患者。

临床怎么用

  • 对于FESS术后难治性CRS且基线皮质醇正常的患者,可考虑使用2 mg每日两次大容量鼻窦莫米松冲洗12周。
  • 治疗期间需注意排查近期全身或局部激素暴露对皮质醇检测的干扰。

局限性

  • 样本量小(14例),为前瞻性队列研究,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medically refractory chronic rhinosinusitis (CRS) is often treated with functional endoscopic sinus surgery (FESS) and high-volume steroid nasal irrigation. While budesonide is the most common steroid irrigation for this indication, mometasone has a superior pharmacokinetic profile, which may allow dose escalation. The safety and efficacy of mometasone at higher concentrations than previously used in treating CRS have not been explored. METHODS: Patients were recruited from a tertiary level clinic between June 2018 and December 2019. Inclusion criteria included adults (>18 years); CRS diagnosis; previous FESS; pre-treatment morning cortisol within normal range; minimum of twice daily high-volume sinonasal mometasone irrigations (total dose of 4 mg) for 12 weeks; and post-treatment morning cortisol measured within 2 weeks following the study period. Patients with potential for endogenous or exogenous disruption of the HPA axis were excluded. RESULTS: 14 patients were enrolled in this prospective cohort study. In all but one patient, pre- and post-treatment morning cortisol levels were not significantly different and were within normal limits (6.7-25.4 μg/dL). Following an uninterrupted 12-week treatment course, no evidence of HPA axis suppression was found (P = 0.915). The single patient who was found to have a low (1.3 μg/dL) post-treatment morning serum cortisol level reportedly received an intraarticular steroid shot several days prior to the blood draw. She remained asymptomatic and her rechecked serum cortisol was within normal limits at 12.3 μg/dL. CONCLUSIONS: High-volume 2 mg twice daily sinonasal mometasone irrigations did not cause HPA axis suppression in a representative sample of patients with refractory CRS post-FESS with normal baseline cortisol levels.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Brown HJ, Batra PS, Eggerstedt M, et al. The possibility of short-term hypothalamic-pituitary-adrenal axis suppression with high-volume, high-dose nasal mometasone irrigation in postsurgical patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2021. PMID: 34569177. doi:10.1002/alr.22894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。